DSNKY Daiichi Sankyo Company, Limited (ADR) Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
05:58
May 12
Hiroyuki Okuzawa President and CEO Bloomberg Markets
Strong product growth drives continued upside.
Daiichi Sankyo's flagship oncology products are growing strongly, with one expected to reach nearly 1 trillion yen in annual sales and another above 100 billion yen. Despite conservative guidance, the fundamental business is robust and will drive continued growth over the next five years.
DSNKY 1ST
HIGH
13:00
Apr 30 ◎
Rob Davis CEO, Merck & Co., Inc. MRK Q1 FY26 call
The FDA priority review highlights continued progress for the Daiichi Sankyo-partnered ADC program in small cell lung cancer.
DSNKY
HIGH

About DSNKY Analyst Coverage

Buzzberg tracks DSNKY (Daiichi Sankyo Company, Limited (ADR)) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (50%). 2 total trade ideas tracked. Latest voices: Hiroyuki Okuzawa, Rob Davis.